IMMUNIC INC
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
IMUX$8.04+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Nine Months Ended September 30, 2024 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
| Shares · Amount | ||||||
| Balance at January 1, 2024 | 45,177,730 | $4 | $436,060 | $3,759 | $(410,892) | $28,931 |
| Net loss | — | — | — | — | (29,584) | (29,584) |
| Stock-based compensation | — | — | 2,750 | — | — | 2,750 |
| Foreign exchange translation adjustment | — | — | — | 528 | — | 528 |
| Issuance of common stock and pre-funded warrants - January 2024 Financing, net of issuance costs of $4,037 | 44,751,286 | 4 | 52,360 | — | — | 52,364 |
| Conversion of tranche rights liability to equity | — | — | 28,396 | — | — | 28,396 |
| Issuance of common stock - At The Market Sales Agreement net of issuance costs of $6 | 150,000 | — | 191 | — | — | 191 |
| Balance at March 31, 2024 | 90,079,016 | $8 | $519,757 | $4,287 | $(440,476) | $83,576 |
| Net loss | — | — | — | — | (21,380) | (21,380) |
| Stock-based compensation | — | — | 1,882 | — | — | 1,882 |
| Foreign exchange translation adjustment | — | — | — | (505) | — | (505) |
| Balance at June 30, 2024 | 90,079,016 | $8 | $521,639 | $3,782 | $(461,856) | $63,573 |
| Net loss | — | — | — | — | (24,368) | (24,368) |
| Stock-based compensation | — | — | 1,910 | — | — | 1,910 |
| Foreign exchange translation adjustment | — | — | — | 104 | — | 104 |
| Balance at September 30, 2024 | 90,079,016 | $8 | $523,549 | $3,886 | $(486,224) | $41,219 |
| Nine Months Ended September 30, 2023 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
| Shares · Amount | ||||||
| Balance at January 1, 2023 | 39,307,286 | $4 | $427,925 | $3,035 | $(317,280) | $113,684 |
| Net loss | — | — | — | — | (25,272) | (25,272) |
| Stock-based compensation | — | — | 1,979 | — | — | 1,979 |
| Foreign exchange translation adjustment | — | — | — | 776 | — | 776 |
| Shares issued from exercise of pre-funded warrants | 5,096,552 | — | 51 | — | — | 51 |
| Balance at March 31, 2023 | 44,403,838 | $4 | $429,955 | $3,811 | $(342,552) | $91,218 |
| Net loss | — | — | — | — | (23,999) | (23,999) |
| Stock-based compensation | — | — | 1,798 | — | — | 1,798 |
| Foreign exchange translation adjustment | — | — | — | 171 | — | 171 |
| Shares issued in connection with the Company's Employee Stock Purchase Plan | 84,533 | — | 96 | — | — | 96 |
| Balance at June 30, 2023 | 44,488,371 | $4 | $431,849 | $3,982 | $(366,551) | $69,284 |
| Net loss | — | — | — | — | (22,769) | (22,769) |
| Stock-based compensation | — | — | 1,687 | — | — | 1,687 |
| Issuance of common stock - At The Market Sales Agreement net of issuance costs of $9 | 107,012 | — | 282 | — | — | 282 |
| Foreign exchange translation adjustment | — | — | — | (77) | — | (77) |
| Balance at September 30, 2023 | 44,595,383 | $4 | $433,818 | $3,905 | $(389,320) | $48,407 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.